Expression of the antimicrobial peptide beta-defensin-2 in the conjunctival epithelial cells in primary open-angle glaucoma and over time in the postoperative period

The time course of changes in the postoperative expression of the antimicrobial peptide beta-defensin-2 (HBD-2) in the conjunctival epithelial cells was studied in 13 patients (13 eyes) with primary open-angle glaucoma (POAG) and 9 individuals (9 eyes) without ophthalmopathology. Scrapes from the ey...

Full description

Saved in:
Bibliographic Details
Published inVestnik oftal'mologii Vol. 126; no. 2; p. 19
Main Authors Erichev, V P, Gankovskaia, L V, Koval'chuk, L V, Gankovskaia, O A, Dugina, A E
Format Journal Article
LanguageRussian
Published Russia (Federation) 01.03.2010
Subjects
Online AccessGet more information

Cover

Loading…
More Information
Summary:The time course of changes in the postoperative expression of the antimicrobial peptide beta-defensin-2 (HBD-2) in the conjunctival epithelial cells was studied in 13 patients (13 eyes) with primary open-angle glaucoma (POAG) and 9 individuals (9 eyes) without ophthalmopathology. Scrapes from the eyelid conjunctiva and transient folds were used as a material for an immunological study. In the study group, the scrapes were taken a few hours before and at 7, 30, and 90 days after surgery. The expression of the HBD-2 gene in the study material was determined by real-time polymerase chain reaction. In the subjects without pathology of the organ of vision, the conjunctival epithelial cells exhibited HBD-2; in the patients with POAG, the baseline HBD-2 gene expression was significantly higher. The baseline HBD-2 expression did not depend on gender, the duration of local antihypertensive therapy, the stage of disease stage, and the level of ophthalmotonus. HBD-2 gene expression was by 5-10 times higher than that preoperatively in all the patients with POAG on postoperative day 7. One month after surgery, the HBD-2 gene expression considerably rose in 31% of the examined patients while it became normal in 38% of the patients.
ISSN:0042-465X